Giovanni Brandi

Featured in: Favicon

nature.com Favicon

tandfonline.com Favicon

thelancet.com Favicon

futuremedicine.com Favicon

jhep-reports.eu Favicon

Articles

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions - Nature Reviews Clinical Oncology

Feb 29, 2024 | nature.com | Yohann Loriot |Giovanni Brandi

AbstractFibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal development and contributes to tissue and whole-body homeostasis, but can also promote tumorigenesis. Various agents, including pan-FGFR inhibitors (erdafitinib and futibatinib), FGFR1/2/3 inhibitors (infigratinib and pemigatinib), as well as a range of more-specific agents, have been developed and several have entered clinical use.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →